No Adverse event; Administered the Dark Pink Cap and Label with Yellow Box instead of Dark Blue Cap and Label with Gray Border. Patient received 0.2 ml of the Dark Pink Cap and Label with Yellow Box.; Administered the Dark Pink Cap and Label with Yellow Box instead of Dark Blue Cap and Label with Gray Border. Patient received 0.2 ml of the Dark Pink Cap and Label with Yellow Box.; patient received it as their 2nd dose after receiving the monovalent Pfizer vaccine as their first dose; patient received it as their 2nd dose after receiving the monovalent Pfizer vaccine as their first dose; This spontaneous case was reported by a physician and describes the occurrence of WRONG PRODUCT ADMINISTERED (Administered the Dark Pink Cap and Label with Yellow Box instead of Dark Blue Cap and Label with Gray Border. Patient received 0.2 ml of the Dark Pink Cap and Label with Yellow Box.), INCORRECT DOSE ADMINISTERED (Administered the Dark Pink Cap and Label with Yellow Box instead of Dark Blue Cap and Label with Gray Border. Patient received 0.2 ml of the Dark Pink Cap and Label with Yellow Box.), COVID-19 IMMUNISATION (patient received it as their 2nd dose after receiving the monovalent Pfizer vaccine as their first dose), INTERCHANGE OF VACCINE PRODUCTS (patient received it as their 2nd dose after receiving the monovalent Pfizer vaccine as their first dose) and NO ADVERSE EVENT (No Adverse event) in a 1-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.    Co-suspect product included non-company product TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for an unknown indication.    No relevant medical history or condition were reported.  Concomitant products included POVIDONE-IODINE (COVIDON) for an unknown indication.   On 24-Apr-2023, the patient received second dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) .2 milliliter. On an unknown date, the patient received first dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (unknown route) 1 dosage form. On 24-Apr-2023, the patient experienced WRONG PRODUCT ADMINISTERED (Administered the Dark Pink Cap and Label with Yellow Box instead of Dark Blue Cap and Label with Gray Border. Patient received 0.2 ml of the Dark Pink Cap and Label with Yellow Box.), INCORRECT DOSE ADMINISTERED (Administered the Dark Pink Cap and Label with Yellow Box instead of Dark Blue Cap and Label with Gray Border. Patient received 0.2 ml of the Dark Pink Cap and Label with Yellow Box.), COVID-19 IMMUNISATION (patient received it as their 2nd dose after receiving the monovalent Pfizer vaccine as their first dose) and INTERCHANGE OF VACCINE PRODUCTS (patient received it as their 2nd dose after receiving the monovalent Pfizer vaccine as their first dose). On an unknown date, the patient experienced NO ADVERSE EVENT (No Adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (Administered the Dark Pink Cap and Label with Yellow Box instead of Dark Blue Cap and Label with Gray Border. Patient received 0.2 ml of the Dark Pink Cap and Label with Yellow Box.), INCORRECT DOSE ADMINISTERED (Administered the Dark Pink Cap and Label with Yellow Box instead of Dark Blue Cap and Label with Gray Border. Patient received 0.2 ml of the Dark Pink Cap and Label with Yellow Box.), COVID-19 IMMUNISATION (patient received it as their 2nd dose after receiving the monovalent Pfizer vaccine as their first dose), INTERCHANGE OF VACCINE PRODUCTS (patient received it as their 2nd dose after receiving the monovalent Pfizer vaccine as their first dose) and NO ADVERSE EVENT (No Adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No Adverse event) to be not related. No further causality assessments were provided for WRONG PRODUCT ADMINISTERED (Administered the Dark Pink Cap and Label with Yellow Box instead of Dark Blue Cap and Label with Gray Border. Patient received 0.2 ml of the Dark Pink Cap and Label with Yellow Box.), INCORRECT DOSE ADMINISTERED (Administered the Dark Pink Cap and Label with Yellow Box instead of Dark Blue Cap and Label with Gray Border. Patient received 0.2 ml of the Dark Pink Cap and Label with Yellow Box.), COVID-19 IMMUNISATION (patient received it as their 2nd dose after receiving the monovalent Pfizer vaccine as their first dose) and INTERCHANGE OF VACCINE PRODUCTS (patient received it as their 2nd dose after receiving the monovalent Pfizer vaccine as their first dose).    Treatment information was not provided.  This case contains information about patient 2nd out of 2 patients.   This case was linked to US-MODERNATX, INC.-MOD-2023-735142 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-735142:same reporter/different patient